Innovate

Forced degradation study design that is both defensible and efficient requires insight into the specific reactivity of an API before work begins in the lab. For a structurally complex molecule, each ICH Q1A(R2) stress condition can implicate multiple functional groups and competing degradation pathways, the challenge is not generating predictions, but knowing which degradation sites

Nitrosamine qualification remains one of the most complex and fast-moving areas in pharmaceutical safety assessment. As scientific understanding advances and regulatory expectations continue to evolve, organisations are increasingly looking beyond one-size-fits-all approaches to support confident, scientifically justified decisions. In our recent webinar, Science-led approaches to nitrosamine qualification and safety assessment, Dr Joel Bercu and Dr

Join us for a recap of the Lhasa Pharmaceutical Science Symposiums held in Colombia and Argentina in March 2026. Participants gained a clearer understanding of how in silico approaches can be applied to assess a variety of impurities, exploring these tools for themselves during demonstration sessions and through real-world case studies shared by Lhasa Limited.

Understanding the metabolic fate of compounds is a requirement for safe pharmaceutical development. Whether supporting early-stage drug discovery, conducting impurity qualification for generics, or preparing data for regulatory submissions, scientists require transparent, scientifically credible predictions aligned with global guidance. As a member-driven and not-for-profit organisation, we have developed Meteor to meet these needs. Our relaunch

In today’s chemical safety landscape, scientists need reliable data to make confident decisions. Challenges in workflows has resulted in toxicology risk assessment software continuing to evolve alongside the advancements seen across the regulatory landscape and the developing methodologies that meet guidelines. Vitic is Lhasa Limited’s expertly curated toxicity database, developed to support informed decision-making in

Mutagenicity assessment is no longer debated; it is embedded within regulatory science. The more important question today is not whether in silico models should be used, but how confidently and transparently their outputs are interpreted. Under ICH M7, the mutagenic potential of pharmaceutical impurities must be evaluated using two complementary in silico methodologies, one expert

We’re delighted to share that Lhasa Limited has been shortlisted for the Lush Prize 2026 in the Science category, an award recognising research teams whose work is most likely to lead to practical, regulator-accepted non-animal testing approaches. The Lush Prize exists to accelerate the transition to 21st-century toxicology, with the ultimate goal of ending the